Nursing Back to Health

A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players

Soumik Kar

The past two years haven’t exactly been a walk in the park for the pharma sector. Steep price erosion of generic drugs in the US and higher regulatory scrutiny by the US Food and Drug Administration (US FDA) kept revenue from the industry’s largest market under significant pressure. A stronger rupee and disruptions in the domestic market in the form of demonetisation and destocking owing to the GST further compounded the problem for Indian pharma.